COVID-19 research at Rockefeller
Rockefeller research directly related to the basic biology, pathophysiology, prevention, and treatment of COVID-19 is underway in more than 25 laboratories. The projects range from near-term efforts to prevent infection in front-line health care workers and reduce the severity of symptoms in vulnerable populations to longer-term strategies to develop therapeutics and vaccines. The scientists leading these projects are collaborating within Rockefeller and across the scientific community to make rapid progress. Rockefeller’s on-site research hospital is also playing a critical role.
These are the faculty members whose labs are conducting COVID-19-related research:
Strategy for immediate deployment
, Physician-in-Chief of The Rockefeller University Hospital, is leading immediate efforts to develop and test the efficacy of plasma and antibodies taken from recovered COVID-19 patients to stop progression in the critically ill and prevent infection in people at high risk such as frontline healthcare workers who have frequent exposure. Rockefeller will apply technologies they have pioneered to purify the genes that encode potent anti-SARS-CoV-2 antibodies, providing a permanent resource that can treat and prevent infection. This funding supports the establishment of a robust infrastructure in NYC to screen and recruit patients, collect plasma and immune cells, and test the efficacy of immune therapies, done in partnership with the New York Blood Center and other leading New York institutions.
CONVALESCENT PLASMA FOR NEAR-TERM PROPHYLAXIS AND TREATMENT
Virologists Paul Bieniasz
and Theodora Hatziioannou
are developing a simplified and rapid method to assess the level of neutralizing antibodies in recovered patient’s blood. The immune systems of recovered patients have produced antibodies that neutralize the virus, preventing it from infecting their cells again. The same antibodies can be transferred to other people—particularly front-line health care workers and the elderly—to prevent or treat infection. A single dose of plasma can typically be effective for more than a month. This use of ‘convalescent plasma’ has enormous potential to provide near-term protection to at-risk populations while longer term efforts are progressing.
DEVELOPMENT OF HIGHLY POTENT MONOCLONAL ANTIBODIES FOR PROPHYLAXIS AND TREATMENT
Immunologist Michel Nussenzweig
pioneered a robust method to isolate and clone broadly neutralizing antibodies (bNAbs) from people who have successfully fought viral infections. He has effectively used this method to develop an antibody-based treatment for prevention and control of established HIV infection. His HIV therapy has been the focus of clinical trials, at The Rockefeller University Hospital, under the direction of physician-scientist Marina Caskey
. Dr. Nussenzweig and his network of national and international collaborators are poised to adapt this powerful approach to discover and characterize potent bNAbs to COVID-19 and related strains of coronaviruses that might produce human infections in the future.
OPTIMIZATION OF ANTIBODIES
Immunologist Jeffrey Ravetch
studies Fc receptors, antibody-binding molecules that are crucial to triggering an immune response and to stopping it once a threat has been neutralized. He will study antibodies made by people who have been infected with SARS-CoV-2 to determine which Fc variants are best capable of eliminating virus.
RAPID SCREENING TESTS FOR SARS-COV-2
Physician-scientist Bob Darnell
is working on new methods to rapidly diagnose infection and develop a model by which patients could do simple at-home sample collection. The rapid testing can be implemented in weeks, which will also be important for quickly identifying members of the local workforce who have acquired infection and preventing spread.
IDENTIFYING THOSE NO LONGER AT RISK OF COVID-19
Biochemist Tom Tuschl
is seeking to develop a rapid and sensitive blood-drop antibody test to determine who has been exposed to the virus. This will be important for assessing and following the health of the population, and will be critical in ascertaining who is no longer at risk of becoming infected or spreading the disease—crucial information for sustaining the workforce in health care facilities.
UNDERSTANDING THE COURSE OF SARS-COV-2 INFECTION
Biochemist and physician Tom Sakmar
is developing a coronavirus calendar, which starts with people who report symptoms and provide a saliva sample every day for up to 90 days. At the end of the evaluation period, the saliva samples can be assayed for presence of viral RNA. These studies will provide critical information about how the infection begins and propagates through the population.
NANOBODIES FOR PREVENTION AND TREATMENT OF COVID-19
Nanobodies are a novel class of small antibody-like molecules. Because of their size and simplicity, they can be manufactured at low cost, have high stability, low immunogenicity, and can be of very high affinity, making them excellent candidates for therapeutics and diagnostics. Because of their high stability, they can be a rapid point-of-care diagnostic and can potentially be used for inhaled delivery to the lungs. Structural biologist Michael Rout
and chemist Brian Chait
will select high affinity and potently neutralizing nanobodies that bind to different sites on the virus. They will format these nanobodies to improve affinity and test which have greater neutralizing ability.
In the near term, virologist Charlie Rice,
who won the Lasker Award for developing the methods that enabled high throughput screens that led to the cure for Hepatitis C, is developing related high-throughput assays to screen for new inhibitors of SARS-CoV-2 replication. He is collaborating with Fraser Glickman
, who directs the university’s High Throughput and Spectroscopy Resource Center, and has assembled a large collection of registered drugs from around the world that have been safe in humans but have not been registered for any therapy. Success with any of these would have a rapid route to FDA approval and clinical use.
NEW TARGETS FOR THERAPY
a human geneticist, has identified many genes whose mutation causes unusual susceptibility to infectious agents such as the bacterium that causes tuberculosis or the influenza virus. As co-leader of an international consortium
, he is now collecting DNA samples from patients who have had unexpectedly severe courses of COVID-19 or who have had many exposures but remained free of disease. This approach has the potential to identify host targets that mediate susceptibility or infection in the cells that become infected and in cells of the immune system that fight infection.
In an approach complementary to Rice's and Casanova's, Erich D. Jarvis
and his colleagues are focusing specifically on ACE2, the receptor used by coronavirus to infect host cells. The receptor is present in many animals, but only some are susceptible to the virus. Jarvis's team is sequencing the genomes of various species to identify structural differences in the ACE2 receptor that might explain differences in susceptibility.
IDENTIFICATION OF NEW LEADS FOR THERAPEUTICS: RNA-DEPENDENT RNA POLYMERASE.
Chemist Sean Brady
has pioneered the discovery of novel antibiotics made by bacteria in soil, using novel methods that do not require the isolation and culture of these bacteria. He has extended this work to the human microbiome, where he has shown that there are many novel nucleosides that are likely involved in inhibition of RNA and DNA polymerases made by different bacteria and viruses. These provide a large untapped source for identifying new leads for a potent and specific inhibitor of the SARS-CoV-2 RNA polymerase.
IDENTIFICATION OF NEW LEADS FOR THERAPEUTICS: HELICASE
SARS-CoV-2 has an essential helicase that is required for unwinding double-stranded RNA templates during viral replication. It is likely that inhibitors of this enzyme can be found that are specific for the virus without effects on human proteins. Tarun Kapoor
is an exceptional chemical biologist with extensive experience on this class of molecule. He will collaborate with Charlie Rice
to identify novel compounds that inhibit the SARS-CoV-2 helicase that can be taken into the clinic.
NEW ANIMAL MODELS FOR TESTING
Immunologist Gabriel Victora
will use his expertise in CRISPR technology to make the mouse ACE2 receptor—where the SARS-CoV-2 virus attaches—identical to its human counterpart. This has the potential to be an ideal model, enabling the next step in advancing drug candidates toward clinical testing. Gabriel will also characterize how antibodies that prevent SARS-CoV-2 infection act, focusing on mapping where they bind, and identifying antibodies that might be potent combinations for therapy and prevention.
BASIC SCIENCE TO DESIGN BETTER DRUGS
Structural biologists Seth Darst
and Elizabeth Campbell
are experts in determining the structure of RNA polymerase complexes bound to the templates that they copy. The SARS-CoV-2 RNA polymerase is essential for viral replication and a prime target for drug treatment. By understanding—in atomic-level detail—how existing inhibitors bind and inhibit the enzyme, they can identify ways to modify current inhibitors to make them specifically effective against SARS-CoV-2. In collaboration with biochemist Brian Chait
, they will also identify all the proteins comprising the RNA replication complex in living cells.
Immunologist Sasha Tarakhovsky
is studying the role of SARS-CoV-2 Nucleocapsid Phosphoprotein on virus-induced cell death in infected cells. He has identified the likely viral protein responsible for this effect and is working to understand the mechanism, with a goal of finding ways to prevent its re-occurrence.
SYNTHETIC HUMAN LUNGS PLATFORM TO STUDY SARS-COV-2 INFECTION
The rational design of COVID-19 therapies will require understanding the life cycle of the virus as it infects human lung cells. In collaboration with virologist Charles Rice, stem cell biologist Ali Brivanlou and his team have, for the first time, generated three-dimensional, self-organized human lung tissue on microchips. These standardized synthetic human “lungs” can be infected with SARS-CoV-2 virus variants and visualized using a variety of reporters. The invisible enemy is now finally visible. The study uses sophisticated molecular imaging and artificial intelligence approaches to gain a basic knowledge for the virus’s behavior, a required step for the design of biological or chemical treatments for COVID-19.
BLOOD CLOTTING COMPLICATIONS IN COVID-19
Many seriously ill COVID-19 patients have increased blood clotting, which can lead to heart attacks and strokes, and is potentially fatal. Neuroscientists Sidney Strickland
and Erin Norris
, and their colleagues, have conducted extensive research on blood clotting in the context of neurodegenerative diseases. They are now applying their expertise to investigate the mechanisms that lead to abnormal blood clotting after SARS-CoV-2 infection. The ability to inhibit this complication could provide a better outcome for some patients.
DETECTION OF SARS-COV-2 USING CRISPR NUCLEASES
has pioneered the research of CRISPR-Cas systems, elucidating their function at the molecular level. CRISPR nucleases use a small RNA guide to recognize and cleave complementary nucleic acid sequences. Dr. Marraffini and his team have programmed the nuclease Cas13 with guide RNAs that specifically recognize the SARS-CoV-2 viral genome and coupled it with different reporter assays that generate a signal to detect the presence of the coronavirus in different human samples. This method could be used for rapid testing for the presence of viral infection.
BIOPHYSICAL CHARACTERIZATION OF THE VIRAL REPLICATION MACHINERY
Biophysicist Shixin Liu
uses high-resolution biophysical tools to investigate the operating principles of key enzymes that govern the SARS-CoV-2 life cycle. He is collaborating with Tarun Kapoor
to elucidate the mechanism by which the viral helicase unwinds its physiological nucleic acid substrates for replication. This investigation will pave the way for identifying specific and potent small molecules that inhibit the enzyme activity.
MUCOSAL IMMUNOGENETICS AND AN ORAL THERAPY FOR COVID-19
Immunologist Daniel Mucida
and cancer biologist Sohail Tavazoie
are studying the immunologic response to SARS-CoV-2 in the lungs and intestines. Though there has been limited focus on the interaction of the virus with the intestinal immune system, an in-depth understanding of the intestinal immune regulation of SARS-CoV-2 is essential for the development of effective therapeutics and vaccine strategies. Dr. Tavazoie’s lab has identified genes that regulate metastatic progression by impacting immunological response. Using mouse models, Drs. Mucida and Tavazoie will determine if specific genes regulate the ability to clear the virus, while evaluating innate and adaptive immunity, including mucosal T cell and antibody responses. The scientists will also test the ability of RGX-104
, an experimental compound that enhances adaptive immunity, to suppress COVID-19 pathogenesis.
DNA-ENCODED LIBRARY (DEL) TECHNOLOGY AND DRUG DISCOVERY
and his colleagues in the Laboratory of Molecular and Cellular Neuroscience recently developed a DEL platform that will be used to identify small molecule compounds binding a number of SARS-CoV-2 structural and non-structural proteins. These targets are being produced and purified in the laboratory or in collaboration with virologists Paul Bieniasz
and Theodora Hatziioannou
. Hit compounds will be validated for their binding capacity and specificity. Specific lead compounds and coronavirus family broad compounds will be further investigated biologically in-house or in collaboration under the lead of virologist Charles Rice
chairs the university's Institutional Review Board, which will review all COVID-19 projects involving human subjects to ensure that they follow ethical guidelines and federal regulations. Dr. Schlesinger was involved in clinical trials of 11 HIV vaccines and vaccine adjuvants.
See all scientists heading research programs at The Rockefeller University>>